Given that CRC has a wide range of long-term outcomes, PBL IGF2 methylation, as a DNA-based non-invasive blood test, could prove beneficial during follow-up and help identify patients at high risk of disease recurrence and progression. The gene discussed is IGF2; the disease is colorectal carcinoma.